204 related articles for article (PubMed ID: 20399185)
1. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.
Rosenberg MF; Bikadi Z; Chan J; Liu X; Ni Z; Cai X; Ford RC; Mao Q
Structure; 2010 Mar; 18(4):482-93. PubMed ID: 20399185
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional structure of the human breast cancer resistance protein (BCRP/ABCG2) in an inward-facing conformation.
Rosenberg MF; Bikadi Z; Hazai E; Starborg T; Kelley L; Chayen NE; Ford RC; Mao Q
Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1725-35. PubMed ID: 26249353
[TBL] [Abstract][Full Text] [Related]
3. Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z; Bikadi Z; Cai X; Rosenberg MF; Mao Q
Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1100-9. PubMed ID: 20739628
[TBL] [Abstract][Full Text] [Related]
4. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.
Ni Z; Bikadi Z; Shuster DL; Zhao C; Rosenberg MF; Mao Q
Biochemistry; 2011 Sep; 50(37):8057-66. PubMed ID: 21854076
[TBL] [Abstract][Full Text] [Related]
5. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.
Wang H; Lee EW; Cai X; Ni Z; Zhou L; Mao Q
Biochemistry; 2008 Dec; 47(52):13778-87. PubMed ID: 19063604
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
7. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.
Litman T; Jensen U; Hansen A; Covitz KM; Zhan Z; Fetsch P; Abati A; Hansen PR; Horn T; Skovsgaard T; Bates SE
Biochim Biophys Acta; 2002 Sep; 1565(1):6-16. PubMed ID: 12225847
[TBL] [Abstract][Full Text] [Related]
8. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
[TBL] [Abstract][Full Text] [Related]
9. Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.
Takara K; Yamamoto K; Matsubara M; Minegaki T; Takahashi M; Yokoyama T; Okumura K
PLoS One; 2012; 7(2):e30697. PubMed ID: 22355323
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
11. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
12. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
13. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
[TBL] [Abstract][Full Text] [Related]
14. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.
Herzog M; Storch CH; Gut P; Kotlyar D; Füllekrug J; Ehehalt R; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):1-11. PubMed ID: 20936466
[TBL] [Abstract][Full Text] [Related]
16. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
[TBL] [Abstract][Full Text] [Related]
17. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
18. 3D cryo-electron reconstruction of BmrA, a bacterial multidrug ABC transporter in an inward-facing conformation and in a lipidic environment.
Fribourg PF; Chami M; Sorzano CO; Gubellini F; Marabini R; Marco S; Jault JM; Lévy D
J Mol Biol; 2014 May; 426(10):2059-69. PubMed ID: 24630999
[TBL] [Abstract][Full Text] [Related]
19. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
20. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]